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Background: Arterial disease in women will become a major issue in the near future.
Methods: A systemic review of existing literature was retrospectively conducted to collect information on the three most
common entities of vascular disease: carotid atherosclerotic, abdominal aortic aneurismal, and lower extremity arterial
occlusive disease.
Results: Vascular disease is either underdiagnosed or undertreated in women. Whether regarding cerebrovascular disease,
aortic aneurysmal disease, or atherosclerosis affecting the lower extremities, natural history, clinical and physiologic
patterns are different in women vs men. Current biomedical devices create challenges in endovascular procedures
performed in women. Furthermore, indications for treatment of vascular disease are derived from large studies where
women are often underrepresented; and, thus, may not be applicable in female vascular patients.
Conclusions: Better understanding of the gender differences in vascular disease with focused randomized trials, biomedical
research, and identification of gender specific medical and social risk factors will improve the clinical outcomes in female
patients. ( J Vasc Surg 2007;46:1295-302.)Increases in the human life span over the course of the
20th century have produced significant changes in demo-
graphic characteristics of the US population. In 1900, only
39% of persons survived to age 65; in 2000, in contrast, 86%
of individuals survive to age 65, and 58% survive to age 80.1
Sociologic and epidemiologic reports have shown that
the majority of these elderly individuals are expected to be
women. In the United States, in 1995, elderly women
outnumbered elderly men ten to seven. Among the octo-
genarians, women outnumbered men by a 5:2 ratio (pop-
ulation resource center- www.prcdc.org and U.S. Census
Bureau- International Data Base- www.census.gov/ipc).
Women are three times more likely than men to survive into
their nineties, they have about 5 to 7 years longer lifespan
than men and because they also on average pair with older
men are very likely to outlive their spouses.
According to the population resource center (www.
prcdc.org)2 and AARP data,3 among those women 65- to
75 years old, almost half of them (48%) live alone without
spouse compared to only 22% of their male counterparts.
Furthermore, since on average women are younger than
their spouses, women are more likely to be relatively
healthy and available to provide care when their husbands
become disabled.2 However, they likely have no one to care
for them when they become frail; the alternative is an
extended care facility.2 In fact one in nine women (10%)
age 75 or older, and one in five age 85 or older, cannot live
independently at home without professional assistance.3
Therefore, elderly women become disproportionate users
of extended care facilities; 75% to 90% of the current
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Multicenter disease-based analyses and other reports on
nursing home residents have indicated that peripheral vas-
cular disease (documented as admitting diagnosis or sug-
gested by documented symptoms or signs) is present in
21% to 67% of the residents4,5 and, therefore, it probably
contributes to their disability that caused their admission to
the extended care facility. It is therefore in society’s interest
to identify early vascular disease in elderly women and
appropriately treat as indicated by the nature and degree of
their disease in an effort to maintain their independency
and function and keep them away from extended care
facilities.
The behavior of arterial disease, whether it be occlusive
or aneurysmal, is different in women than men in terms of
anatomy, physiology, and clinical manifestations. Many
types of vascular disease are more difficult to treat in
women, possibly due to the fact that older women have
smaller and less compliant arteries than men.6 Moreover,
since women have been underrepresented in all major
randomized trial and we know less about the natural history
of their vascular disease. By reviewing the existing litera-
ture, we have identified three distinct vascular disease pro-
cesses where there are obvious and significant gender-
related differences (carotid artery stenosis, aneurysmal
disease, and lower extremity arterial occlusive disease). It is
imperative that these differences be considered when caring
for the female patient. Each disease process is considered
separately below.
WOMEN AND CAROTID STENOSIS
Because of the high prevalence of carotid bifurcation
atherosclerosis and the observed benefit of interventional
treatment, carotid procedures, whether endarterectomy or
stenting, are among the most commonly performed proce-
dures by vascular surgeons or interventionalists. There are
distinct anatomic and pathophysiologic differences in ca-
rotid disease in women vs men. The carotid and vertebral
arteries are significantly smaller,6-8 the vessel wall is less
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women than in men.10 These characteristics likely explain
why for the same degree of carotid stenosis, velocities are
higher in women than in men. Comerota et al showed that
in all carotid segments, duplex ultrasound revealed veloci-
ties that were 6% to 9% higher in women than in men.11
This data, although certainly needs further investigation
with carefully designed studies, may imply that criteria for
determining carotid stenosis in women may be different
than for men; all of the criteria that are used for determin-
ing carotid stenosis were derived from studies of patients of
both genders. Although differences in velocities between
genders are 10% or less, knowledge of these differences is
likely to be useful to the clinician when determining the
need for surgery in female patients where the indications
for carotid angiogram or surgery are borderline, such as
elderly symptomatic, or young asymptomatic women with
moderate to severe carotid disease.
The exact prevalence of carotid stenosis in women is
not well known. Data from the American vascular associa-
tion screening program showed that50% carotid stenosis
was less frequent in women compared to men (6% vs 8%,
P  .03).12 The average age of these patients was 68 years.
Therefore, the prevalence of carotid disease is likely to
increase in the older female population in a similar manner
with lower extremity occlusive and aneurysmal disease, but
this needs further investigation. Smoking has the strongest
association with carotid disease in women as in men. Other
significant independent risk factors are menopause, hyper-
cholesterolemia, and age.13 Women on average present
with greater degree stenosis for the amount of plaque that
they have when compared to men because they have more
focal lesions.14 Usually, the plaque is more stable with a
higher smooth muscle cell and collagen and less cholesterol
content.15 The maximal stenosis is usually in the carotid
bulb and external carotid artery in contrast with men where
the stenosis is more prominent in the origin of the internal
carotid.10 Although carotid plaques appear to be more
benign in women, they are likely to be a predictor of
generalized atherosclerosis, which places women with ca-
rotid disease at high risk for cardiovascular events. Epide-
miologic studies from the Framingham community based
cohort have shown a graded and strong association in
women between C-reactive protein (CRP) and carotid
arteriosclerosis that is not seen in men.16 High-sensitivity
CRP (hs-CRP) is one of the strongest risk identifiers of
cardiovascular disease in women17 among other inflamma-
tory markers or adhesion molecules, associated with high
cardiovascular risk in women and significantly altered dur-
ing menopause, such as serum amyloid A interleukin-617
and I-CAM18, TNF a.19 The significant role of sex hor-
mones prior and after menopause and hormone replace-
ment therapy on these inflammatory markers associated
with progression of atherosclerotic disease has been re-
cently recognized, and it is currently an intriguing research
subject for many ongoing studies.
Growing evidence suggests a strong but so far poorly
understood link between osteoporosis and carotid disease:osteoporosis is highly prevalent in patients with acute first
stroke from carotid artery stenosis. Alternatively, echogenic
plaque in elderly women might serve as a marker of ad-
vanced osteoporosis.20-22 The clinical significance of this
association needs further investigation.
When it comes to clinical outcomes and indications for
carotid intervention, it is clear that women were underrep-
resented in the three large prospective randomized studies
of carotid disease: North American symptomatic carotid
endarterectomy trial (NASCET) had 30% women partici-
pants, the VA Cooperative trial had 0% women, asymptom-
atic carotid artery study (ACAS) included 33%, and asymp-
tomatic carotid surgery trial (ACST) 34%women, therefore
the indications for intervention in women were not well
defined. These trials overall, demonstrated a benefit of
carotid endarterectomy in the general population, in
asymptomatic greater than 60% carotid artery stenosis and
symptomatic more than 50% stenosis. Although these trials
were not powered to specifically evaluate a female cohort,
they did identify important trends among women that have
raised more questions than they have answered. Findings
include: (1) In the NASCET trial, there was no benefit
from carotid endarterectomy (CEA) when performed in
women with moderate symptomatic (50% to 69% lumen
reduction) stenosis. (2) The benefit in asymptomatic
women undergoing CEA was borderline in ACAS (17%
relative risk reduction in women compared to a 66% reduc-
tion in men). This was in part due to a higher perioperative
rate of complication (stroke, transient ischemic attack
[TIA], or death) in women (3.6%) relative to men (1.7%).
(3) At any age, the risk for stroke was less in women than in
men. (4) For any degree of stenosis, the risk of stroke was
less in women than in men. (5) Multivariate analysis has
demonstrated that female gender is an independent predic-
tor of postoperative TIA or stroke, especially in asymptom-
atic females with carotid stenosis. (6) The benefit of CEA
for asymptomatic disease in women may require longer
follow-up periods to be evident (ACST). An increased
perioperative risk for women undergoing CEA has also
been demonstrated in retrospective single institutional
studies23 but not in others.24-27
There is significant evidence in literature from both
randomized and retrospective studies that women have a
threefold overall higher risk for recurrent carotid stenosis
compared to men. When primary closure is used instead of
patch closure, then the risk of restenosis in women increases
to fivefold compared to men.23,28-30 Therefore, in the
authors’ opinion, patch angioplasty should be considered
routinely in women undergoing CEA.
The observed increase in risk of perioperative stroke
and increased restenosis rate may be in part the result of
technical issues related to the small size of the female
carotid artery, although other factors are likely in play.
Lastly, data from small retrospective trials suggests that
hormone replacement therapy negatively impacts the rate
of stroke, at both 30 days and 5 years, for women who have
undergone carotid endarterectomy. Gender differences re-
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to be evaluated in large trial studies.
WOMEN AND AORTIC ANEURYSMAL DISEASE
The infrarenal aorta is significantly smaller in women
than in men. According to sonographic findings in healthy
individuals, this gender specific difference in diameter
ranges from 2.3 to 4 mm.31 Because of these differences, a
uniform definition of aneurysmal disease across genders is
not possible. For both women andmen, the aortic diameter
enlarges with age while aortic compliance decreases; how-
ever, these changes occur after menopause in women and
usually become more pronounced during the sixth and
seventh decade.9,32,33 The reason for this is still unclear
and likely multifactorial. Probably sex hormones play major
role on aortic wall compliance by regulating the collagen/
elastin ratio and matrix metalloproteinase (MMP) activity.
This role changes dramatically during menopause. This has
been suggested so far by studies in mouse models. Female
sex hormones appear to increase the elastin/collagen ra-
tio34 and decrease of MMP-9 activity.35 MMP-9 is one of
the main metalinoproteinases that are strongly associated
with aneurismal formation and it increases up to three
to fourfold in patients with abdominal aortic aneurysm
(AAA).36-38 In fact, female mice demonstrate lower
MMP-9 levels and resistance to experimental AAA forma-
tion by inhibiting MMP-9 activity. Estrogen absence re-
verses the metalinoproteinase effect and elastin to collagen
ratio even in female rat aortas transplanted in male ro-
dents.39 Although all this needs further validation in hu-
man subjects, these findings in part, explain why women
who undergo intervention for aortic aneurysms are well
into their postmenopausal years and older than men by at
least 4 to 5 years. The principal association of abdominal
aortic aneurysms with smoking and family history is all
similar in women compared to men.40 In three studies,
there was a strong association between cerebrovascular
disease and AAA in women not seen in men,40-42 while an
additional study has also shown that black race and cancer
are more often associated with AAA in women than in
men.40 Finally, in two studies, AAA in women is less
frequently associated with femoral and popliteal aneu-
rysms43,44 and more frequently associated with iliac occlu-
sive disease44 compared to men.
The use of a standardized aortic diameter (ie, 3 to 3.5
cm) to define aneurysmal disease in both genders, may lead
to underreporting of the disease in women which as ex-
plained above, are known to have smaller starting size of the
aorta.45 The fact that aneurysmal disease presents later in
life in women, when they are likely to live alone, may lead to
less frequent medical evaluations in women which in turn
could contribute to a lower rate of detection. Interestingly
and supporting this hypothesis, in autopsy studies the prev-
alence of abdominal aortic aneurysms is 2.25% in women
and 3.6% in men over 70 years, numbers that are quite
similar. However, in large clinical studies (such as ADAM
and UK Small Aneurysm Trial) where patients with already
identified aneurysms were evaluated, there are significantgender related differences in the prevalence of AAAs 3.0 cm
or greater (1% in women vs 4.3% in men). As well, many
epidemiologic and screening studies have revealed male to
female ratios that range from 4.8 to 5.0:1.0.40,44,46,47
The prevalence of AAA in women has implications with
regard to screening. A recent report by the US Preventive
Service Task Force has recommended that ultrasound
screening for AAA be performed for male smokers 65
years of age; however, the task force recommended against
screening in women. The logic of a recommendation
against screening in women, regardless of their risk profile,
appears to be related to evidence that AAA prevalence is
lower in females and that AAA occurs later in life in females
vs males. Factors that appear to not have been considered
by the authors of the Task Force is (1) the significantly
higher rupture rate that has been observed in women vs
men with AAA, (2) the higher AAA prevalence found in
womenwith cardiovascular risk factors or older in age (75
years old), or (3) the significantly increased longevity of
females vs men. All of these factors were recently intro-
duced into a detailed Markov model where the cost-effec-
tiveness of screening for AAA in women was evaluated.
Screening for womenwhen these factors are considered was
found to be quite cost-effective. The diminished prevalence
of AAA in women was counterbalanced in this analysis by
the significantly higher rate of rupture.48 Recent findings
from our own group reveal that the prevalence of AAA in
women with risk factors can be in the range of 4% to 6%.49
Clearly, more data is needed. However, until further stud-
ies are available, the authors feel that screening should be
considered in women 60 to 85 years of age with cardiovas-
cular risk factors or a family history.
Despite a lower incidence of AAA, the rupture rate is at
least three times higher for women than inmen and rupture
occurs in aneurysms of smaller size. For instance, in the
United Kingdom small aneurysm trial (UKSAT) study, the
mean diameter of the ruptured aneurysms in women was 5
cm; in men, it was 6 cm. Also, based on older studies50 as
well as recent data from a Medicare outcome analysis,47
approximately 30% to 34% of ruptured AAAs that result in
death in the United States, occur in women. These num-
bers contrast with the fact that only 22.6% of elective AAA
repairs are performed in women. These data suggest that
either women with AAA are not being diagnosed, or that
repair is not being offered for AAA at a size that prevents
rupture. Smaller aneurysms tend to rupture in women
probably because the starting point of the aortic size is less
in females, and probably, the percent increase in diameter
when they do rupture is the same in both genders. Gender
specific difference in the aortic compliance may be another
reason. However, all this needs further validation. Never-
theless, lack of broad recognition that AAAs rupture at
smaller size in womenmay contribute to less optimal care of
women with aneurismal disease.
Although endovascular therapies have revolutionized
and simplified the treatment of the abdominal aortic
aneurysm, these techniques present unique challenges in
female patients: (1) Large retrospective studies derived
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have shown that endovascular treatments are less frequently
offered to women compared to men (endografting was
performed in only 28% to 32.4% of women compared to
44.3% to 46.7% of men.47,51 (2) The aortic anatomy of
women is different from that of men in ways that make
endovascular repair more challenging (shorter aortic necks,
smaller iliac vessels, and probably, more iliac occlusive
disease). Consequently, women have more access related
complications52 and limb occlusion after stent graft place-
ment53 than men. (3) Women also have a 1.7 higher rate of
endoleak.54 These data suggest that the design of en-
dografts may need to be gender specific. (4) On a positive
note, women may have more rapid shrinkage of the aneu-
rysmal sac after endografting compared to men; women less
frequently require multiple graft extensions and have peri-
operative mortality after endografting that is close to that of
men (3.1 vs 2.6%).47,52
For open aneurysm repair, the perioperative mortality
in women is still significantly greater than for men (6.57% vs
4% to 4.75% - Medicare data 2003 and 2004). Moreover,
length of stay in the hospital after AAA repair is longer with
women, and fewer women are likely to be discharged home
relative to men (70.1 % vs 84.5%, respectively).47 The
higher numbers of women who are not discharged home
might imply the different sociologic factors associated with
the elderly women undergoing AAA repair, since large
portion of the female population at this age either live alone
or are responsible for spousal care. This deserves further
evaluation.
Improvements in AAA management over the last de-
cade have decreased overall aneurysm related death and the
incidence of rupture; however, these decreases are confined
exclusively to men. The risk of rupture has not diminished
at all in women51,55 and a higher percentage of women
(21% vs 16% men) currently present with rupture. This fact
should be considered when caring for females with AAA; it
is clear that the management of females with aneurysms
should differ from that of their male counterparts.
Finally, sexual dysfunction has been well characterized
after aortic surgery (for occlusive or aneurysmal disease) in
men. However, there is limited information on women.
Few reports on this subject suggest significant difficulty in
gathering meaningful information from possible female
patients, because of the advanced age, social circumstances
(widows or no sexual partner) of many patients, and a
general reluctance to answer explicit questions about their
sexual function.56 From these limited reports, it appears
that postoperative sexual dysfunction might be less pro-
nounced in women than in men,56,57 probably because
female sex organs are internal with highly collateralized
blood supply and female sensual sensation is mostly depen-
dent on the endofascially placed pudental nerves that are
better protected against trauma during aortic surgery com-
pared to the periaortic nerve plexuses that play major role
on male sexual arousal.58 These more recent findings are
very different from earlier reports on limited number of
female patients with aortic occlusive disease, showing sig-nificant negative impact of both the disease and surgical
treatment on postoperative sexual function.59 All these
prove the fact that the effects of surgical treatment of the
aortic disease either be aneurysmal or occlusive on the
female sexual function are very poorly evaluated and war-
rant more focused future investigation.
WOMEN AND LOWER EXTREMITY ARTERIAL
OCCLUSIVE DISEASE
Recent data report 5 to 7 million adults in the United
States60,61 suffer from lower extremity arterial occlusive
disease. However, there is a general bias that the prevalence
of lower extremity arterial occlusive disease is less in women
than in men. To some extent this is true because hormonal
and metabolic factors through the manipulation of specific
estrogen receptors, inflammatory factors and lymphokines,
adhesion molecules, lipoproteins, and growth factors,17-19
create an atheroprotective environment in premenopausal
women through mechanisms that are not totally under-
stood. However, arterial occlusive disease in women in-
creases significantly during menopause and after. As such,
the incidence of disease in women and men in their sixth
and seventh decades is at least identical. Interestingly,
several community based surveys recently report higher
rates of lower extremity arterial disease in women compared
to men.62,63 The prevalence of lower extremity arterial
occlusive disease among women is as low as 3% to 4.4% in
population of 40-year-olds or older and increases to 15.5%
to 29% in those aged 80 years or older.64,65
Overall, risk factors for lower extremity occlusive arte-
rial disease appear to be similar in men and women, al-
though women with peripheral vascular disease are signifi-
cantly less likely than men to be smokers. Recent findings
suggest that hormone replacement therapy do not protect
women against peripheral vascular disease, and it might
increase peripheral vascular events during the first years
of treatment (Women’s Health Initiative Estrogen Alone
Trial,66 the Heart and Estrogen/Progestin Replacement
Study,67 and the Women’s Health Initiative Estrogen Plus
Progestin Trial).68 Finally, there is emerging evidence of a
strong but still not well understood association between
lower extremity vascular disease and osteoporosis with a
threefold increase in the prevalence of vascular disease in
postmenopausal women with osteoporosis compared to
their counterparts without osteoporosis.69
Women who are screened appear to have more asymp-
tomatic disease when compared to men. However, when
women seek medical help, they have more advanced dis-
ease; they more often than men require amputation as first
line vascular procedure.12,70,71 The reasons for this are not
well understood, but a number of hypotheses have been
ventured. Older women are often socially isolated or they
take care of an older sicker spouse and often neglect them-
selves. They are also more likely to have financial issues that
prevent them from seeking prompt medical assistance. Re-
cent AARP data72 have shown significantly lower income in
women age 65 and older (almost half that of men) as well as
significantly higher poverty rates compared to their male
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creased risk of having an amputation compared with high-
income patients.71 Finally, in women, arterial symptoms
are often masked by symptoms related to osteoporosis and
arthritis which are also prominent in this patient group.73
Diagnostic studies, such as the ankle-brachial index
(ABI), are valuable screening tools diagnosing lower ex-
tremity arterial occlusive disease in women. They detect
vascular disease at three to five times the frequency than
would be found using history or symptoms alone. Even
more important is the finding that an ABI 0.9 is strongly
correlated in an otherwise healthy appearing women with a
high overall cardiovascular mortality.74 As such, it has been
suggested, particularly in women, that ABIs be used as a
screening tool to identify women that might benefit from
aggressive risk factor modification.
Significant information comparing outcomes of arterial
reconstruction in women to men comes from a multitude
of single institution studies75-84 and systemic reviews of the
literature.85,86 There is no much concern regarding the
role of gender on aortoiliac reconstruction; the long-term
operative outcomes appear similar across genders in routine
and relatively young high-risk patients.83,87,88
For lower extremity bypass, although individual reports
might be conflicting when compiled together,75-82,84 have
not shown a significant statistical difference in patency
rates, limb salvage, or overall survival between genders.
However, in these studies, males and females were not
matched for age and comorbidities. In most of these stud-
ies, there were more male smokers than female.
Studies did show a consistently higher rate of wound
complications in women relative to men75,76,81 Interest-
ingly, in all these three studies75,76,81 there was higher
incidence of diabetes in the female group of patients com-
pared to the male group, and therefore, this finding could
have contributed to the higher incidence of wound com-
plications. However, in two separate studies that are ana-
lyzing risk factors associated with wound complications
after infrainguinal reconstruction, female gender was found
to be an independent risk factor for wound dehiscence with
suppurative soft-tissue infection in patients undergoing
autogenous vascular bypass grafting when results were con-
trolled for obesity, diabetes, and other contributing param-
eters.89,90 This observation may reflect differences in me-
tabolism as well as fat content and distribution in the upper
thighs. Diabetes may be a more ominous marker for car-
diovascular morbidity and mortality after peripheral recon-
struction in women vs men. Diabetic women in many
studies suffered a greater number of cardiovascular compli-
cations.80,79 Women on hormone replacement therapy
have less favorable outcomes with lower extremity bypass
with lower 1-, 3-, and 5-year patency rates, relative to their
counterparts who are not on hormonal replacement.91
There is currently lack of substantial evidence demon-
strating differences in the outcomes after lower extremity
endovascular interventions. There have been a few single
institution studies that have demonstrated significant dif-
ferences between men and women treated with percutane-ous iliac interventions, with women having decreased im-
mediate and long-term patency rates.92 These differences
were most evident in one study in women undergoing
external iliac artery interventions; a fourfold increase in
stent failure was observed in women relative to men.93
Univariate and Cox regression analyses identified hormone
replacement therapy (HRT) use and stent placement in the
external iliac artery as independent predictors of decreased
primary patency. Data regarding infrainguinal endovascular
is scarce. In one paper,94 the authors compared the out-
comes between genders from 351 angioplasties in 248
patients (173 women, 178 men) undergoing percutaneous
transluminal angioplasty over a 10-year period. From these
procedures, almost half (177) were infrainguinal interven-
tions. They found no gender specific differences in the
outcomes of either iliac or infrainguinal angioplasties.
Women, though, were more likely than men to be treated
for femoropopliteal as opposed to iliac disease. These re-
sults are somewhat similar to the ones from our institution
where in a total of 447 percutaneous infrainguinal interven-
tions performed in 309 women followed up over a 2-year
period, we observed no difference in primary, secondary
patency, and limb salvage compared to 553 interventions in
men.95 Interestingly, treated women had more advanced
disease compared to men in terms of symptoms and TASC
classification. Further studies would be necessary to define
the efficacy and safety of endovascular intervention in
women and identify specific anatomic and clinical factors
with negative impact to the outcomes.
WOMEN ON HRT AND PERIPHERAL
ARTERIAL DISEASE (PAD)
Hormone replacement therapy was frequently pre-
scribed to postmenopausal women until 1998. Then in
1998 and 2002, two large prospective trials produced new
findings regarding the effect of the estrogen and proges-
tin combination on PAD in women with coronary artery
disease (the Heart and Estrogen/Progestin Replace-
ment Study67) and in healthy postmenopausal women
(the Women’s Health Initiative Estrogen Plus Progestin
Trial).68 Both studies demonstrated that the combination
hormonal therapy had no protective effect against the
development of peripheral vascular disease. More impor-
tantly, in the active treatment group, there was an increase
in peripheral vascular events in the early years of the study;
however, this effect dissipated thereafter. Smaller retrospec-
tive studies have also revealed a negative impact of HRT
therapy on patency rates for specific arterial reconstructions
such as external iliac artery angioplasty (see preceding para-
graph).
In 2004, the prospective Women’s Health Initiative
Estrogen Alone Trial was prematurely terminated because
findings early in its course that demonstrated unfavorable
outcomes. A significantly higher incidence of stroke and
early arterial events were identified in the treatment
group.66 Therefore, HRT, combination or single agent,
should be considered a significant risk factor in womenwith
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SUMMARY
Arterial vascular disease is a significant problem for
women in our aging society. The average woman is ex-
pected to live 30 to 40 years following menopause and 5 to
7 years longer than their male counterparts. Whether con-
sidering cerebrovascular pathology, aneurysms or athero-
sclerosis affecting the lower extremities, vascular disease is
either underdiagnosed or undertreated in women. The
clinical and physiologic patterns are different in women vs
men, which creates challenges in management. Further-
more, indications for treatment of vascular disease are
derived from large studies where women are often under-
represented; thus, the results of these studies may not be
applicable in the population of female vascular patients. It is
our responsibility as vascular surgeons to develop expertise
on the natural history, disease patterns, and outcomes of
treatment in order to provide optimal care for women with
vascular disease.
Recommendations towards achieving this goal might
include:
(1) The development of randomized trials that are specif-
ically focused on women including trials focused on
new interventional therapies.
(2) Further clarify gender related risk factors such as hor-
mone replacement therapy, osteoporosis diabetes and
obesity that will affect the progression of disease and
outcomes of treatment in women.
(3) Evaluate the impact of social factors/isolation and
institutionalization on the outcome of treatments for
vascular disease in women.
Interestingly, NIH has acknowledged the need for
focused research on women’s health. Since July 2000,
through the Office of Research on Women’s Health
(ORWH), it has initiated funding programs that are award-
ing clinical, translational, or behavioral research committed
and geared towards the understanding of cardiovascular
disease in women. Increasing our understanding of the
gender differences in vascular disease will ensure an overall
improvement in societal health.
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